Daniel R Reed
Overview
Explore the profile of Daniel R Reed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerra-Resendez R, Lydon S, Ma A, Bedford G, Reed D, Kim S, et al.
ACS Synth Biol
. 2025 Feb;
14(2):384-397.
PMID: 39898483
Nuclease-deactivated Cas (dCas) proteins can be used to recruit epigenetic effectors, and this class of epigenetic editing technologies has revolutionized the ability to synthetically control the mammalian epigenome and transcriptome....
2.
Mort J, Brighton D, DiBenedetto S, Wells L, Clark S, Reid J, et al.
Eur J Haematol
. 2024 Nov;
114(3):481-494.
PMID: 39601208
Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical...
3.
Reed D, Lum L
Expert Opin Biol Ther
. 2024 Jul;
24(8):761-772.
PMID: 39069893
Introduction: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded...
4.
Mahata B, Cabrera A, Brenner D, Guerra-Resendez R, Li J, Goell J, et al.
Nat Methods
. 2023 Oct;
20(11):1716-1728.
PMID: 37813990
Engineered transactivation domains (TADs) combined with programmable DNA binding platforms have revolutionized synthetic transcriptional control. Despite recent progress in programmable CRISPR-Cas-based transactivation (CRISPRa) technologies, the TADs used in these systems...
5.
Cheng J, Tooze J, Callahan K, Pajewski N, Pardee T, Reed D, et al.
J Geriatr Oncol
. 2023 Jul;
14(7):101509.
PMID: 37454532
Introduction: Assessing frailty is integral to treatment decision-making for older adults with acute myeloid leukemia (AML). Prior electronic frailty indices (eFI) derive from an accumulated-deficit model and are associated with...
6.
Reed D, Wooster M, Isom S, Ellis L, Howard D, Manuel M, et al.
Ann Hematol
. 2023 Mar;
102(4):897-906.
PMID: 36856803
Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study...
7.
Reed D, Petroni G, West M, Jones C, Alfaraj A, Williams P, et al.
Hematol Oncol Stem Cell Ther
. 2023 Jan;
16(1):61-69.
PMID: 36634280
Objective/background: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ...
8.
Fitzpatrick M, Sundaram V, Ly A, Abramson J, Balassanian R, Cheung M, et al.
Cancer Cytopathol
. 2022 Dec;
131(5):279-288.
PMID: 36573933
Background: Few studies have evaluated diagnostic yield of small volume biopsies (SVB) for the diagnosis and management of follicular lymphoma (FL). Methods: The authors performed a multi-institutional retrospective analysis of...
9.
Volaric A, Lin O, Balassanian R, Cook S, Falchi L, Fitzpatrick M, et al.
Am J Surg Pathol
. 2022 Dec;
47(2):212-217.
PMID: 36537240
Small-volume biopsies (SVBs) including fine-needle aspiration (FNA), cell block, and needle core biopsies (NCB) are increasingly utilized to diagnose and guide the clinical management of lymphoma. We established a multi-institutional...
10.
Shantzer L, Dougherty S, Bolte F, Melson J, Reed D, Lynch A, et al.
Clin Lung Cancer
. 2022 Dec;
24(2):e60-e64.
PMID: 36526550
No abstract available.